In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...
Labware for 3D cell culture, low-bind labware, and glycan analysis kits are designed to accelerate life science ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...
Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I would like to hand things over to Mr. Edward Chung. Please go ahead, sir. Good ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results